Bevacizumab biosimilar - Biocad

Drug Profile

Bevacizumab biosimilar - Biocad

Alternative Names: BCD-021

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocad
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Non-small cell lung cancer

Most Recent Events

  • 30 Mar 2016 Biocad terminates phase I trial in Wet age-related macular degeneration in Russia (NCT02450981)
  • 30 Mar 2016 Biocad terminates the GALATIR trial in Wet age-related macular degeneration in Brazil and Russia (NCT02036723)
  • 09 Dec 2015 Registered for Non-small cell lung cancer (Combination therapy, Late-stage disease) in Sri Lanka (IV) after December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top